Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes

Table 2

Percent of Days with HSV-2 Viral Shedding.

Population ITTC		Valacyclovir	Placebo	𝑃-value	% Reduction
		(𝑛=52)	(𝑛=52)
Period 1	𝑛	25	27
	Mean (SD %)	3.0 (4.6)	14.3 (16.6)
	Range	0–17	0–68
Period 2	𝑛	27	25
	Mean (SD %)	2.9 (6.5)	12.6 (17.4)
	Range	0–29	0–61
Overall	𝑛	52	52
	Mean (SD %)	2.9 (5.6)	13.5 (16.9)	<.001	78
	Range	0–29	0–68
ITT Period 1	𝑛	30	35	<.001	83
	Mean (SD %)	2.6 (4.3)	14.9 (18.3)
Other Efficacy Parameters
ITTC		Valacyclovir (𝑛=52)	Placebo (𝑛=52)	𝑃-value
Percent days with subclinical shedding, Mean (SD %)		2.4 (4.8)	11 (15.1)	<.001
Percent days with clinical shedding, Mean (SD %)		0.6 (1.7)	2.4 (4.4)	.014
Subjects with no Shedding, 𝑛 (%)		31 (60)	15 (29)	<.001
Proportion of subjects recurrencefree, 𝑛 (%)		41 (79)	27 (52)	.003
Median time to first genital herpes recurrence^a (days)		>68	61	.010

^aFirst treatment period.